4-((1-((1-naphtyl)methyl)-5-methoxybenzimidazole)-2-ylthio)butyric acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-((1-((1-naphtyl)methyl)-5-methoxybenzimidazole)-2-ylthio)butyric acid
• 英文别名: 4-((1-((1-naphthyl)methyl)-5-methoxybenzimidazole)-2-ylthio)butyric acid；4-[5-Methoxy-1-(naphthalen-1-ylmethyl)benzimidazol-2-yl]sulfanylbutanoic acid
• 化学式: C₂₃H₂₂N₂O₃S
• 分子量: 406.505
• InChiKey: NKVBEMRESARZNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  89.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 lithium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 生成 4-((1-((1-naphtyl)methyl)-5-methoxybenzimidazole)-2-ylthio)butyric acid
  参考文献：
  名称：

  EP1167360

  摘要：

  公开号：

文献信息

• Human chymase inhibitors
  申请人：——

  公开号：US20030083315A1

  公开（公告）日：2003-05-01

  The present invention provides a benzimidazole derivative or its. pharmaceutically permissible salt expressed by the following formula (1). Further, the present invention provides a human chymase activity inhibitor containing the substance as an active ingredient. 1 (the ring marked with A expresses a pyridline ring or a benzene ring; X 1 and X 2 are each a hydrogen atom, a halogen atom, a trihalomethyl group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, or the like; B is a substituted or unsubstituted alkylene group, or the like; E is —COOR 4 or the like; G is a substituted or unsubstituted alkylene group; J is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; and M is a sulfur atom, sulfoxidde, sulfone or the like).

  本发明提供了一种由以下公式（1）表示的苯并咪唑衍生物或其药学上可接受的盐。此外，本发明提供了一种含有该物质作为活性成分的人类钴胺酶活性抑制剂。其中（A标记的环表示吡啶环或苯环；X1和X2分别是氢原子，卤素原子，三卤甲基基团，氰基，取代或未取代的烷基基团，取代或未取代的烷氧基团等；B是取代或未取代的烷基烃基团等；E是—COOR4或类似物；G是取代或未取代的烷基烃基团；J是取代或未取代的烷基基团或取代或未取代的芳基基团；M是硫原子，亚硫氧化物，砜或类似物）。
• HUMAN CHYMASE INHIBITORS
  申请人：TEIJIN LIMITED

  公开号：EP1167360A1

  公开（公告）日：2002-01-02

  The present invention provides a benzimidazole derivative or its pharmaceutically permissible salt expressed by the following formula (1). Further, the present invention provides a human chymase activity inhibitor containing the substance as an active ingredient. (the ring marked with A expresses a pyridine ring or a benzene ring; X1 and X2 are each a hydrogen atom, a halogen atom, a trihalomethyl group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, or the like; B is a substituted or unsubstituted alkylene group, or the like; E is -COOR4 or the like; G is a substituted or unsubstituted alkylene group; J is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; and M is a sulfur atom, sulfoxide, sulfone or the like).

  本发明提供了一种苯并咪唑衍生物或由下式（1）表示的其药学上允许的盐。此外，本发明还提供了一种含有该物质作为活性成分的人糜蛋白酶活性抑制剂。 (标有 A 的环表示吡啶环或苯环；X1 和 X2 各为氢原子、卤素原子、三卤甲基、氰基、取代或未取代的烷基、取代或未取代的烷氧基或类似基团；B 是取代或未取代的亚烷基或类似基团；E 是-COOR4 或类似基团；G 是取代或未取代的亚烷基；J 是取代或未取代的烷基或取代或未取代的芳基；M 是硫原子、亚砜、砜或类似基团）。
• EP1167360A9
  申请人：——

  公开号：EP1167360A9

  公开（公告）日：2002-05-15
• Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
  申请人：Talley John Jeffrey

  公开号：US20090054319A1

  公开（公告）日：2009-02-26

  The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.
• EP1167360
  申请人：——

  公开号：——

  公开（公告）日：——